Cargando…
ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction
AIMS: The prevalence of heart failure with preserved ejection fraction (HFpEF) is still increasing, and so far, no pharmaceutical treatment has proven to be effective. A key obstacle for testing new pharmaceutical substances is the availability of suitable animal models for HFpEF, which realisticall...
Autores principales: | Schauer, Antje, Draskowski, Runa, Jannasch, Anett, Kirchhoff, Virginia, Goto, Keita, Männel, Anita, Barthel, Peggy, Augstein, Antje, Winzer, Ephraim, Tugtekin, Malte, Labeit, Siegfried, Linke, Axel, Adams, Volker |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524062/ https://www.ncbi.nlm.nih.gov/pubmed/32710530 http://dx.doi.org/10.1002/ehf2.12915 |
Ejemplares similares
-
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF
por: Schauer, Antje, et al.
Publicado: (2021) -
Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility
por: Adams, Volker, et al.
Publicado: (2022) -
Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model
por: Winzer, Ephraim B., et al.
Publicado: (2022) -
Leucine Supplementation Improves Diastolic Function in HFpEF by HDAC4 Inhibition
por: Alves, Paula Ketilly Nascimento, et al.
Publicado: (2023) -
Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)